22.05.2013 - Danish Novo A/S has strengthened its pipeline of anti-infectives against multidrug resistant bugs by acquiring Norwegian Xellia Pharmaceuticals.
The holding company of the Danish insulin producer Novo Nordisk purchased all shares of Xellia from 3i and other shareholders. As a consequence of the US$700m transaction, Xellia’s headquarters will move from Oslo to Copenhagen. The API manufacturer, which was spun-out from Alpharma Inc in 2008, is the leading supplier of the last resort antibiotic Vancomycin, the Gram-negative killing drug Colistimethate Sodium (CMS), antifungal medicines and corticosteroids.
Xellia has built a pipeline of generic anti-infective treatments, and has extensive semi-synthetic and biological manufacturing know-how, including strain development and manufacturing. Novo's investment will allow Xellia to boost its R&D and to improve its market reach.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more